Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Fallopian Tube Cancer Clinical Trials

A listing of Fallopian Tube Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (9) clinical trials

Women with Ovarian, Fallopian Tube or Primary Peritoneal Cancers are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.

Phase N/A

Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer Localized Prostate Cancer or Gynecological Cancer

OBJECTIVES: Primary - To test the hypothesis that an association between common genetic variations, reported by single nucleotide polymorphisms (SNP) in relevant candidate genes, is associated with individual patient variability in normal tissue radiation response and toxicity. Secondary - To compare different clinical scoring systems for late normal tissue effects, ...

Phase N/A

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

This is an open-label (identity of assigned study drug will be known) study to evaluate the safety, pharmacokinetics (study of what the body does to a drug), pharmacodynamics (study of what a drug does to the body), and anti-tumor activities of STM 434 (an inhibitor of activin A) in patients ...

Phase

A Study of Coti-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies

This is a single arm, single center, open-label, Phase 1, first time in human study of COTI-2 in patients with recurrent ovarian,fallopian tube,primary peritoneal cancer, endometrial, cervical or head and neck cancer. COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free ...

Phase

Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer

This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)

Phase

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

7 cohorts of first-line chemotherapy regimens combined with durvalumab + tremelimumab. This study will evaluate the safety and tolerability of durvalumab (MEDI4736) + tremelimumab in combination with first line chemotherapy regimens in patients with locally advanced or metastatic solid tumors: ovarian/peritoneal/fallopian tube cancer, squamous cell carcinoma of the head and ...

Phase

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers, including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia ...

Phase

Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian Fallopian Tube Or Peritoneal Cancer

Pegylated liposomal doxorubicin (PLD; e.g., Doxil®, Lipodox™) will be administered intravenously on Day 1 and EGEN-001 will be administered intraperitoneally on Day 1, 8, 15, and 22 of a 28-day cycle to determine: - The maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of EGEN-001 when administered in combination ...

Phase

An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (OTILIA)

This observational study will evaluate the safety, efficacy, quality of life and predictive/selection factors for Avastin (bevacizumab) in combination with carboplatin/paclitaxel in first line in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in clinical practice. Data of eligible patients will be collected during up to 15 ...

Phase N/A